Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice
- PMID: 30609118
- PMCID: PMC6590288
- DOI: 10.1002/jcb.28308
Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice
Abstract
The expression of programmed death ligand-1 (PD-L1) in tumor has been used as a biomarker to predict the anti-PD-L1 immunotherapy response. To develop a noninvasive imaging technique to monitor the dynamic changes in PD-L1 expression in colorectal cancer (CRC), we labeled an anti-PD-L1 monoclonal antibody with near-infrared (NIR) dye and tested the ability of the NIR-PD-L1-mAb probe to monitor the PD-L1 expression in CRC-xenografted mice by performing optical imaging. Consistent with the expression levels of PD-L1 protein in three CRC cell lines in vitro by flow cytometry and Western blot analyses, our in vivo imaging showed the highest fluorescence signal of the xenografted tumors in mice bearing SW620 CRC cells, followed by tumors derived from SW480 and HCT8 cell lines. We detected the highest fluorescent intensity of the tumor at 120 hours after injection of NIR-PD-L1-mAb. The highest fluorescence intensity was seen in the tumor, followed by the spleen and the liver in SW620 xenografted mice. In SW480 and HCT8 xenografted mice, however, the highest fluorescent signals were detected in the spleen, followed by the liver and the tumor. Our findings indicate that SW620 cells express a higher level of PD-L1, and the NIR-PD-L1-mAb binding to PD-L1 on the surface of CRC cells was specific. The technique was safe and could provide valuable information on PD-L1 expression of the tumor for development of a therapeutic strategy of personized targeted immunotherapies as well as treatment response of patients with CRC.
Keywords: colorectal cancer; immunotherapy; noninvasive imaging; optical imaging; programmed death ligand-1/programmed death ligand-1 checkpoint.
© 2019 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures




Similar articles
-
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.Oncotarget. 2016 Mar 1;7(9):10215-27. doi: 10.18632/oncotarget.7143. Oncotarget. 2016. PMID: 26848870 Free PMC article.
-
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody.Mol Pharm. 2018 Apr 2;15(4):1674-1681. doi: 10.1021/acs.molpharmaceut.8b00062. Epub 2018 Mar 12. Mol Pharm. 2018. PMID: 29502426
-
Activatable near-infrared fluorescence probe for real-time imaging of PD-L1 expression in tumors.J Mater Chem B. 2024 Oct 30;12(42):10877-10885. doi: 10.1039/d4tb01148a. J Mater Chem B. 2024. PMID: 39206756
-
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.Arch Pathol Lab Med. 2018 Jan;142(1):26-34. doi: 10.5858/arpa.2017-0041-RA. Epub 2017 Nov 9. Arch Pathol Lab Med. 2018. PMID: 29120224 Review.
-
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.Biomed Pharmacother. 2019 Feb;110:312-318. doi: 10.1016/j.biopha.2018.11.105. Epub 2018 Dec 3. Biomed Pharmacother. 2019. PMID: 30522017 Review.
Cited by
-
Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel). 2022 Jun 14;15(6):747. doi: 10.3390/ph15060747. Pharmaceuticals (Basel). 2022. PMID: 35745666 Free PMC article. Review.
-
A PD-L1-Targeted Probe Cy5.5-A11 for In Vivo Imaging of Multiple Tumors.ACS Omega. 2024 Oct 17;9(43):43826-43833. doi: 10.1021/acsomega.4c06761. eCollection 2024 Oct 29. ACS Omega. 2024. PMID: 39494025 Free PMC article.
-
In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.Res Sq [Preprint]. 2023 Oct 23:rs.3.rs-3222037. doi: 10.21203/rs.3.rs-3222037/v1. Res Sq. 2023. PMID: 37961361 Free PMC article. Preprint.
-
Identification of a novel peptide targeting TIGIT to evaluate immunomodulation of 125I seed brachytherapy in HCC by near-infrared fluorescence.Front Oncol. 2023 Apr 14;13:1143266. doi: 10.3389/fonc.2023.1143266. eCollection 2023. Front Oncol. 2023. PMID: 37124530 Free PMC article.
-
Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.Int J Nanomedicine. 2023 Sep 8;18:5141-5157. doi: 10.2147/IJN.S417944. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37705867 Free PMC article.
References
-
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immuno‐surveillance to tumor escape. Mat Immunol. 2002;3:991‐998. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous